Jul 2026 (Q2 FY27) — Aug 31, 2026
SAIC Q2 FY27 — Strong Performance Drives Raised Guidance and Strategic Transformation
Read the full callScience Applications International (SAIC) earnings
- Jul 2026
- Jul 2026 (Q2 FY27)
- Jan 2026
Science Applications International earnings: last reported Mon, 31 Aug 2026, for the quarter ended Jul 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 1,880 | +6.3% YoY | Quarterly, as filed | Quarter to Jul 2026 | Revenue from operations as filed. |
| Operating margin | 8.1 | +0.2 pts YoY | Operating profit / revenue | Quarter to Jul 2026 | For the quarter; a change is in percentage points. |
| Net profit | 102 | −19.7% YoY | Quarterly, as filed | Quarter to Jul 2026 | Profit after tax as filed. |
Guidance
What management said, and what became of it
10 of 10 judged targets kept · 15 open · verdicts reflect calls analysed to Apr 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Civilian segment adjusted EBITDA margin (long-term recovery target) | 100 to 150 basis points of improvement over the next few years | Oct 2024 | what we said at the time was expect that mid-12% to be the trough for that business that we would expect this business to operate consistently at 15% or so. And here we are at 15% in the second quarter. | Revised Up |
| FY27 Free Cash Flow (total) | approximately $600 million | Jul 2025 | Our free cash flow outlook of greater than $600 million is unchanged, even as we plan to invest in discrete opportunities in support of growth. | On Track |
| FY26 Adjusted Diluted EPS | $9.10 to $9.30 | Jan 2025 | Adjusted diluted earnings per share was $2.62 in the quarter and $10.75 for the year and benefited from stronger margins and a favorable tax rate, which offset lower revenues. | Achieved |
15 of Science Applications International Corp's 25 targets are still open. See which are on track and which have gone quiet. The 3 above are the free sample; 22 more targets are in the full ledger.
Claimed
- Organic revenue growth of approximately 5% in Q2 FY27.
- Adjusted EBITDA of $193 million with margins of 10.3% in Q2 FY27.
- Free cash flow of $131 million in Q2 FY27, maintaining peer-leading cash conversion.
- Net leverage fell to 3.0x in Q2 FY27.
- Recompete win rate over 90% in Q2 FY27.
- Booked over $1.6 billion of intel space awards in H1 FY27.
Qualified
- Book-to-bill of 0.6x in Q2 FY27, or 0.8x on a trailing 12-month basis, due to large opportunities slipping and slower RFPs/awards.
- Applied second-half revenue contraction reflecting the RITS contract rolling off, creating an approximately 350 basis point headwind.
- Second-half margins expected to step down to the high 9% range from 11% in H1 due to planned investments.
Price
$133.13 +0.05% · +$0.06
Performance +36.5% 1Y
1Y: $97.51 on 17 Oct 2025 → $133.13. High $134.66 (9 Oct 2026), low $82.22 (11 Feb 2026).
- Previous close
- $133.07
- 52-week range
- $82.22 – $134.66
- One year
- +33.80%
Overview
- Symbol
- SAIC
- Sector
- Information Technology
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
10 of 10 judged targets kept · 15 open · verdicts reflect calls analysed to Apr 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Civilian segment adjusted EBITDA margin (long-term recovery target) | 100 to 150 basis points of improvement over the next few years | Oct 2024 | what we said at the time was expect that mid-12% to be the trough for that business that we would expect this business to operate consistently at 15% or so. And here we are at 15% in the second quarter. | Revised Up |
| FY27 Free Cash Flow (total) | approximately $600 million | Jul 2025 | Our free cash flow outlook of greater than $600 million is unchanged, even as we plan to invest in discrete opportunities in support of growth. | On Track |
| FY26 Adjusted Diluted EPS | $9.10 to $9.30 | Jan 2025 | Adjusted diluted earnings per share was $2.62 in the quarter and $10.75 for the year and benefited from stronger margins and a favorable tax rate, which offset lower revenues. | Achieved |
Claimed
- Organic revenue growth of approximately 5% in Q2 FY27.
- Adjusted EBITDA of $193 million with margins of 10.3% in Q2 FY27.
- Free cash flow of $131 million in Q2 FY27, maintaining peer-leading cash conversion.
- Net leverage fell to 3.0x in Q2 FY27.
- Recompete win rate over 90% in Q2 FY27.
- Booked over $1.6 billion of intel space awards in H1 FY27.
Qualified
- Book-to-bill of 0.6x in Q2 FY27, or 0.8x on a trailing 12-month basis, due to large opportunities slipping and slower RFPs/awards.
- Applied second-half revenue contraction reflecting the RITS contract rolling off, creating an approximately 350 basis point headwind.
- Second-half margins expected to step down to the high 9% range from 11% in H1 due to planned investments.
The full ledger
Open Science Applications International Corp’s full ledger
A free account opens 5 company ledgers a month. All 25 tracked commitments, with each call’s wording and source.
Call summaries
Apr 2026 (Q1 FY27) — Jun 1, 2026
SAIC Q1 FY27 — Strong Margins and Cash Flow Drive Raised Guidance
Read the full callJan 2026 (Q4 FY26) — Mar 16, 2026
SAIC Q4 FY26 — Strong Margin and Cash Flow Despite Revenue Contraction
Read the full callEvery analysed call
Science Applications International earnings calls (SAIC)
Financials
What the filings say
Net profit, year on year: −20% (quarter to jul 2026 against aug 2025).
| Line item | Nov 2024 | Jan 2025 | May 2025 | Aug 2025 | Oct 2025 | Jan 2026 | May 2026 | Jul 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,976 | 1,838 | 1,877 | 1,769 | 1,866 | 1,750 | 1,906 | 1,880 |
| Operating profit | 160 | 138 | 121 | 139 | 128 | 133 | 179 | 152 |
| Operating margin | 8.1% | 7.5% | 6.5% | 7.9% | 6.9% | 7.6% | 9.4% | 8.1% |
| Interest | 32 | — | — | — | — | — | — | — |
| Profit before tax | 126 | 107 | 86 | 108 | 94 | 99 | 145 | 119 |
| Tax rate | 15.9% | 8.4% | 20.9% | −17.6% | 17.0% | 14.1% | 20.7% | 14.3% |
| Net profit | 106 | 98 | 68 | 127 | 78 | — | 115 | 102 |
| EPS ($ per share) | 2.15 | — | 1.43 | 2.72 | 1.70 | — | 2.63 | 2.41 |
| Line item | Feb 2019 | Jan 2020 | Jan 2021 | Jan 2022 | Feb 2023 | Feb 2024 | Jan 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | 367 | 506 | 627 | 818 | 1,035 | 1,432 | 1,565 | 1,492 |
| Total liabilities | 3,064 | 3,284 | 4,171 | 4,117 | 3,839 | 3,529 | 3,669 | 3,854 |
| Fixed assets | 103 | 91 | 108 | 100 | 92 | 91 | 104 | 110 |
| Total assets | 4,563 | 4,711 | 5,723 | 5,746 | 5,543 | 5,314 | 5,246 | 5,354 |
| Line item | Feb 2019 | Jan 2020 | Jan 2021 | Jan 2022 | Feb 2023 | Feb 2024 | Jan 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 184 | 458 | 755 | 518 | 532 | 396 | 494 | 609 |
| Cash from investing | -1,028 | -47 | -1,231 | -292 | -36 | 314 | -35 | -248 |
| Cash from financing | 938 | -455 | 464 | -301 | -493 | -725 | -498 | -235 |
| Net cash flow | 94 | -44 | -12 | -75 | 3 | -15 | -39 | 126 |
| Capital expenditure | -28 | -21 | -46 | -36 | -25 | -27 | -36 | -32 |
| Free cash flow | 156 | 437 | 709 | 482 | 507 | 369 | 458 | 577 |
SAIC revenue by segment
| Segment | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Q4 FY2026 | Q1 FY2027 | Q2 FY2027 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Defense and Intelligence | 77% | 74% | 76% | 78% | 77% | 76% | 77% | 77% | +5.5% |
| Civilian | 23% | 26% | 24% | 22% | 23% | 24% | 23% | 23% | +9.1% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
SAIC operating KPIs by quarter
| KPI | Jan 2026 Q4 FY26 | Apr 2026 Q1 FY27 | Jul 2026 Q2 FY27 | Change vs prior quarter |
|---|---|---|---|---|
| Book-to-bill ratio | — | 1.1 ratioThis resulted in a quarterly book-to-bill of 1.1x or 1.0x on a trailing 12-month basis.Source: earnings call transcript | 0.6 ratioThis resulted in a quarterly book-to-bill of 0.6,x, or 0.8x on a trailing 12-month basis.Source: earnings call transcript | -45.5% |
| Employees | 23KI think at least once or twice every week, I get an e-mail from one of our 23,000 employees applauding what we're doing and giving me some real-life examples of things that we could do differently to help them get their jobs done easier.Source: earnings call transcript | 23KI want to recognize our 23,000 employees whose relentless commitment to execution excellence made these results possible sustaining strong margins and industry-leading cash flow reflects the team's discipline and focus in a dynamic environment.Source: earnings call transcript | — | 0% |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Insider filings
60 filings between Oct 24, 2025 and Sep 22, 2026.
Open market
decisions to buy or sellPurchases
$478.7K
7 purchases by 6 insiders
Sales
None
No insider sold shares.
Compensation
not trading decisions- 25
- Award — granted as compensation
- 2
- Option exercise — converted options into shares
- 22
- Tax withheld — shares kept back by the company to cover tax
Also filed: 4 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Natarajan Prabu | $201.0K | — | Dec 16, 2025 |
| Cush C. David | $132.5K | — | Sep 22, 2026 |
| REAGAN JAMES | $100.2K | — | Dec 16, 2025 |
| Attili Srinivas | $19.6K | — | Apr 9, 2026 |
| DiFronzo Vincent P. | $15.4K | — | Dec 23, 2025 |
| Hageman Hilary | $10.0K | — | Dec 16, 2025 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 22, 2026 | Cush C. David Director | Purchase | 1,000 | $132.5K |
| Sep 4, 2026 | Benson David C Director | Award | 1,220 | $0 |
| Sep 4, 2026 | DiFronzo Vincent P. EVP,-Air Force & Space, Intel | Award | 4,210 | $0 |
| Sep 4, 2026 | Cush C. David Director | Award | 1,220 | $0 |
| Jul 2, 2026 | DiFronzo Vincent P. EVP,-Air Force & Space, Intel | Gift | 2,682 | $0 |
| Jul 2, 2026 | DiFronzo Vincent P. EVP,-Air Force & Space, Intel | Gift | 2,682 | $0 |
| Jun 6, 2026 | McCarthy Kathleen T. EVP, CHRO | Tax withheld | 1,233 | $141.0K |
| Jun 3, 2026 | MCFARLAND KATHARINA G. Director | Award | 1,886 | $0 |
| Jun 3, 2026 | REAGAN JAMES CEO | Tax withheld | 742 | $84.1K |
| Jun 3, 2026 | Handlon Carolyn B Director | Award | 1,886 | $0 |
| Jun 3, 2026 | Eremenko Paul Director | Award | 2,174 | $0 |
| Jun 3, 2026 | Urban David Director | Award | 1,886 | $0 |
| Jun 3, 2026 | Rogers Michael Scott Director | Award | 2,174 | $0 |
| Jun 3, 2026 | MOREA DONNA S Director | Award | 1,886 | $0 |
| Jun 3, 2026 | Tien John K Jr Director | Award | 1,886 | $0 |
| Jun 3, 2026 | SHANE STEVEN R Director | Award | 1,886 | $0 |
| Jun 3, 2026 | McGuirt Milford W Director | Award | 1,886 | $0 |
| Jun 2, 2026 | SHANE STEVEN R Director | Tax withheld | 1,941 | $223.4K |
| Jun 2, 2026 | SHANE STEVEN R Director | Option exercise | 2,876 | $223.3K |
| Apr 9, 2026 | Attili Srinivas EVP, Civilian | Purchase | 100 | $9.5K |
| Apr 7, 2026 | MOREA DONNA S Director | Tax withheld | 2,243 | $223.3K |
| Apr 7, 2026 | Natarajan Prabu EVP, Chief Financial Officer | Tax withheld | 837 | $83.3K |
| Apr 7, 2026 | MOREA DONNA S Director | Option exercise | 2,876 | $223.3K |
| Apr 7, 2026 | DiFronzo Vincent P. EVP,-Air Force & Space, Intel | Tax withheld | 234 | $23.3K |
| Apr 7, 2026 | Supplee Barbara EVP, Navy, Army | Tax withheld | 245 | $24.4K |
| Apr 7, 2026 | Hageman Hilary EVP General Counsel, Secretary | Tax withheld | 670 | $66.7K |
| Apr 5, 2026 | DiFronzo Vincent P. EVP,-Air Force & Comb Commands | Tax withheld | 195 | $19.5K |
| Apr 5, 2026 | Natarajan Prabu EVP, Chief Financial Officer | Tax withheld | 790 | $79.1K |
| Apr 5, 2026 | Hageman Hilary EVP General Counsel, Secretary | Tax withheld | 604 | $60.5K |
| Apr 5, 2026 | Supplee Barbara EVP, Navy | Tax withheld | 233 | $23.3K |
| Apr 4, 2026 | DiFronzo Vincent P. EVP,-Air Force & Comb Commands | Tax withheld | 351 | $35.1K |
| Apr 4, 2026 | Natarajan Prabu EVP, Chief Financial Officer | Tax withheld | 895 | $89.6K |
| Apr 4, 2026 | Hageman Hilary EVP General Counsel, Secretary | Tax withheld | 685 | $68.6K |
| Apr 4, 2026 | Supplee Barbara EVP, Navy | Tax withheld | 394 | $39.4K |
| Apr 4, 2026 | Attili Srinivas EVP, Civilian | Tax withheld | 285 | $28.5K |
| Apr 3, 2026 | Hageman Hilary EVP General Counsel, Secretary | Award | 5,468 | $0 |
| Apr 3, 2026 | Natarajan Prabu EVP, Chief Financial Officer | Award | 7,571 | $0 |
| Apr 3, 2026 | REAGAN JAMES CEO | Award | 31,543 | $0 |
| Apr 3, 2026 | Attili Srinivas EVP, Civilian | Award | 4,206 | $0 |
| Apr 3, 2026 | Supplee Barbara EVP, Navy | Award | 4,627 | $0 |
| Apr 3, 2026 | McCarthy Kathleen T. EVP, CHRO | Award | 5,047 | $0 |
| Mar 4, 2026 | Supplee Barbara EVP, Navy | Award | 1,572 | $0 |
| Mar 4, 2026 | DiFronzo Vincent P. EVP,-Air Force & Comb Commands | Tax withheld | 1,064 | $100.5K |
| Mar 4, 2026 | Natarajan Prabu EVP, Chief Financial Officer | Tax withheld | 4,274 | $403.6K |
| Mar 4, 2026 | Hageman Hilary EVP General Counsel, Secretary | Tax withheld | 3,439 | $324.7K |
| Mar 4, 2026 | DiFronzo Vincent P. EVP,-Air Force & Comb Commands | Award | 2,517 | $0 |
| Mar 4, 2026 | Hageman Hilary EVP General Counsel, Secretary | Award | 7,542 | $0 |
| Mar 4, 2026 | Supplee Barbara EVP, Navy | Tax withheld | 760 | $71.8K |
| Mar 4, 2026 | Natarajan Prabu EVP, Chief Financial Officer | Award | 9,427 | $0 |
| Feb 17, 2026 | REAGAN JAMES CEO | Tax withheld | 8,861 | $767.5K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Science Applications International Corp
Free account. Everything above stays public.
Write why you follow Science Applications International Corp and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading